Anti-CTLA4 therapy shapes T-cell pool involved in anti-tumor recognition by indiscriminately broadening blood TCR repertoire (which also increase treatment side effects) (40, 41) and by increasing the number of tumor reactive T-cell clones (42, 43). The gene discussed is CTLA4; the disease is neoplasm.